{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:05:13Z","timestamp":1795176313825,"version":"4.10.3"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Invasive pulmonary aspergillosis (IPA) is a significant cause of morbidity and mortality in lung transplant recipients (LTRs). It is unclear how a targeted prophylaxis\/ preemptive antifungal therapy strategy impacts the incidence of IPA beyond the first-year posttransplant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>This is a retrospective cohort of LTRs from January 2010 to December 2014. We included all LTRs who survived beyond the first year and followed them until death or 4 years postoperatively. Incidence of probable\/proven IPA and <jats:italic toggle=\"yes\">Aspergillus<\/jats:italic> colonization were assessed as per International Society for Heart and Lung Transplantation (ISHLT) criteria. Patients with risk factors, positive <jats:italic toggle=\"yes\">Aspergillus<\/jats:italic> cultures, or galactomannan (GM) received targeted prophylaxis\/preemptive therapy within the first-year posttransplant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>During the study period, 350 consecutive LTRs underwent 1078 bronchoscopies. Positive bronchoalveolar lavage for GM or <jats:italic toggle=\"yes\">Aspergillus<\/jats:italic> cultures was reported for 15% (52\/350) of LTRs between 2 and 4 years after transplantation. Among them, the median time to positive <jats:italic toggle=\"yes\">Aspergillus<\/jats:italic> culture or GM positivity was 703 days (interquartile range, 529\u2013754 d). The incidence rate of IPA and <jats:italic toggle=\"yes\">Aspergillus<\/jats:italic> colonization was 30 of 1000 patient-y, and 63 of 1000 patient-y, respectively. The mortality rate was significantly higher in patients with IPA than without IPA (107\/1000 patient-years versus 18\/1000 patient-years; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.0001). Rate of first-year colonization and IPA was 33% and 9%, respectively. Among the 201 patients who had a negative bronchoscopy during the first year posttransplant, only 6 (3%) developed IPA during the follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>A targeted prophylaxis\/preemptive therapy strategy within the first-year posttransplant resulted in 4% incidence of IPA at 4-years after transplantation. However, IPA was associated with higher mortality.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003187","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T05:09:17Z","timestamp":1582261757000},"page":"2575-2581","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Late Onset Invasive Pulmonary Aspergillosis in Lung Transplant Recipients in the Setting of a Targeted Prophylaxis\/Preemptive Antifungal Therapy Strategy"],"prefix":"10.1097","volume":"104","author":[{"given":"Sabina","family":"Herrera","sequence":"first","affiliation":[{"name":"Multi-Organ Transplant Program, Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setareh","family":"Davoudi","sequence":"additional","affiliation":[{"name":"Multi-Organ Transplant Program, Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Farooq","sequence":"additional","affiliation":[{"name":"Multi-Organ Transplant Program, Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi","family":"Tikkanen","sequence":"additional","affiliation":[{"name":"Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Foroutan","sequence":"additional","affiliation":[{"name":"Multi-Organ Transplant Program, Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Kumar","sequence":"additional","affiliation":[{"name":"Multi-Organ Transplant Program, Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Humar","sequence":"additional","affiliation":[{"name":"Multi-Organ Transplant Program, Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleman","family":"Rotstein","sequence":"additional","affiliation":[{"name":"Multi-Organ Transplant Program, Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne G.","family":"Singer","sequence":"additional","affiliation":[{"name":"Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaf","family":"Keshavjee","sequence":"additional","affiliation":[{"name":"Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Husain","sequence":"additional","affiliation":[{"name":"Multi-Organ Transplant Program, Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"R1-20241210","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.healun.2006.12.009","article-title":"Post-operative nosocomial infections after lung and heart transplantation.","volume":"26","author":"Mattner","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R2-20241210","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-6143.2010.03375.x","article-title":"Antifungal prophylaxis in lung transplantation\u2013a world-wide survey.","volume":"11","author":"Neoh","year":"2011","journal-title":"Am J Transplant"},{"key":"R3-20241210","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/tid.12337","article-title":"Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: a national survey.","volume":"17","author":"He","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"R4-20241210","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11908-013-0380-y","article-title":"Anti-Aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis.","volume":"15","author":"Bhaskaran","year":"2013","journal-title":"Curr Infect Dis Rep"},{"key":"R5-20241210","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1469-0691.2005.01128.x","article-title":"Aspergillus infections in lung transplant recipients: risk factors and outcome.","volume":"11","author":"Sol\u00e9","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"R6-20241210","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10096-007-0376-3","article-title":"Aspergillus infection in lung transplant patients: incidence and prognosis.","volume":"26","author":"Iversen","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R7-20241210","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/ajt.12691","article-title":"Epidemiology of invasive mold infections in lung transplant recipients.","volume":"14","author":"Doligalski","year":"2014","journal-title":"Am J Transplant"},{"key":"R8-20241210","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.healun.2018.02.006","article-title":"A strategy for prevention of fungal infections in lung transplantation: role of bronchoalveolar lavage fluid galactomannan and fungal culture.","volume":"37","author":"Husain","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"R9-20241210","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.healun.2016.01.007","article-title":"The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: executive summary.","volume":"35","author":"Husain","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"R10-20241210","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.healun.2011.01.701","article-title":"A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients.","volume":"30","author":"Husain","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R11-20241210","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R12-20241210","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.healun.2018.06.008","article-title":"Clinical risk factors for invasive aspergillosis in lung transplant recipients: results of an international cohort study.","volume":"37","author":"Aguilar","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"R13-20241210","doi-asserted-by":"crossref","first-page":"e12898","DOI":"10.1111\/tid.12898","article-title":"Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort Study.","volume":"20","author":"Neofytos","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"R14-20241210","first-page":"269","article-title":"Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance\u00ae registry analysis.","volume":"55","author":"Husain","year":"2017","journal-title":"Med Mycol"},{"key":"R15-20241210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/tri.12679","article-title":"10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation.","volume":"29","author":"Peghin","year":"2016","journal-title":"Transpl Int"},{"key":"R16-20241210","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/01.TP.0000437434.42851.d4","article-title":"Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis.","volume":"97","author":"Luong","year":"2014","journal-title":"Transplantation"},{"key":"R17-20241210","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1053-2498(02)00477-1","article-title":"Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management.","volume":"22","author":"Singh","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"R18-20241210","doi-asserted-by":"crossref","first-page":"e13544","DOI":"10.1111\/ctr.13544","article-title":"Invasive Aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Husain","year":"2019","journal-title":"Clin Transplant"},{"key":"R19-20241210","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1097\/TP.0000000000000743","article-title":"The effectiveness of culture-directed preemptive anti-Aspergillus treatment in lung transplant recipients at one year after transplant.","volume":"99","author":"Hosseini-Moghaddam","year":"2015","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T17:17:20Z","timestamp":1733851040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003187","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,18]]}}}